Neurotech International (ASX: NTI) advances novel treatment for autism spectrum disorder (w/ Thomas Duthy)

Neurotech International (ASX: NTI) executive director Dr Thomas Duthy joins Small Caps to discuss the company’s progress on its drug NTI164 in treating autism spectrum disorder (ASD) and other paediatric neurological disorders with neuroinflammation. Dr Duthy says NTI164 is a broad-spectrum cannabinoid drug product, which is designed as an oral once-a-day formulation. Neurotech is currently focusing on using NTI164 to treat ASD, where clinical trials are underway and have yielded highly significant results. Articles:https://smallcaps.com.au/neurotech-international-launch-clinical-program-lead-drug-nti164-treat-rett-syndrome/https://smallcaps.com.au/neurotech-clinical-trial-lead-drug-candidate-autism-spectrum-disorder-results/ For more information on Neurotech International: https://smallcaps.com.au/stocks/NTI/See omnystudio.com/listener for privacy information.